Johnson & Johnson said it would pay an estimated $5.5bn to resolve tens of thousands of lawsuits alleging its baby powder and other talc products caused ovarian cancer, in a landmark deal that could end a contentious, decade-long legal battle.
Johnson & Johnson on Monday said the settlement covers about 76,000 claims, including ones consolidated in a federal court in New Jersey, and related cases in state court, representing nearly all of the remaining talc claims against the company.
The US multinational had previously settled most of the cases alleging that its talc contained asbestos and caused mesothelioma.
Plaintiffs’ law firms confirmed the deal on Monday, saying it was a good resolution after a 10-year court battle. The deal must be accepted by 95% of the ovarian cancer claimants in state or federal court before it becomes final.
Johnson & Johnson’s vice-president of litigation, Erik Haas, said the claims were “meritless” and that the company was willing to settle in order to get closure.
“While we are confident the company would have ultimately prevailed with further litigation, as it has in the vast majority of cases tried to date, this resolution allows the company to put this matter behind it and remain focused on its mission to develop medicines and devices that save lives,” Haas said.
Johnson & Johnson expects to pay $3bn in 2027, and it will make further payments in 2028. But the deal could be worth more, depending on how many people participate in the settlement.
Chris Seeger, a lawyer who represents about 2,500 clients with talc claims and helped negotiate the agreement, said Johnson & Johnson could ultimately pay $7bn or more.
The settlement assigns specific values to qualifying ovarian cancer claims but does not cap Johnson & Johnson’s total payout, Seeger said. “We got a fair settlement, and our clients are going to be happy with it.”
Johnson & Johnson reached the settlement after a series of wins in court, including victories in individual trials, successful efforts to disqualify plaintiffs’ lawyers from the litigation, and court rulings against experts that plaintiffs had used to prove their cases in court.
The company, headquartered in New Jersey, won a significant court victory in the long-running legal battle last week, when a federal judge cast doubt on individual plaintiffs’ ability to prove that talc specifically caused their ovarian cancer.
Johnson & Johnson has long denied that its talc products caused cancer, saying that talc was safe and did not contain asbestos.
The company stopped selling talc-based baby powder in the US in 2020, switching to a cornstarch product. But litigation resumed in March 2025, after being put on hold for more than three years while Johnson & Johnson unsuccessfully pursued a strategy known as the “Texas two step”, filing three bankruptcies through a shell-company subsidiary in an effort to settle the cases. Each bankruptcy ended in dismissal.
Before the bankruptcy attempts, Johnson & Johnson had a mixed record in talc trials, with a multibillion dollar verdict in favour of 22 women who said baby powder caused their ovarian cancer. The company won some trials outright and had other verdicts reduced on appeal.
Unlike the proposed bankruptcy settlements, Monday’s agreement applies only to existing claims and does not address future lawsuits.
The exclusion of future claims made more money available to current plaintiffs than the bankruptcy proposal did, and it also accelerates the payments so that all claims will be paid within 18 months instead of being spread out over more than a decade, Seeger said.
